Altiratinib is a selective receptor tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK), making it a significant therapeutic agent for treating non-small cell lung cancer and other… Read more
Altiratinib is a selective receptor tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK), making it a significant therapeutic agent for treating non-small cell lung cancer and other solid tumors characterized by ALK gene rearrangements or mutations. Pharmaceutical laboratories utilize this category of Altiratinib reference standards, including high-purity impurities, metabolites, and stable isotope labelled compounds, to support rigorous analytical testing and quality control processes. These specialized materials are essential for method development and validation, particularly when conducting impurity profiling and quantifying drug levels in biological matrices using techniques like HPLC-MS/MS. By providing accurate benchmarks, these analytical standards assist in ensuring compliance with regulatory requirements throughout the drug development lifecycle, from initial research phases to final batch release testing.